Cybrexa Therapeutics, a New Haven, CT-based biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, completed a $13.4m Series B1 financing.
Backers in the round, which brings total capital raised to date to $21.1m, included CT Innovations, HighCape Capital Special Opportunities Fund, and Cycle Venture Partners.
The company intends to use the funds to advance its first clinical candidate CBX-11 (alphalexTM-rucaparib) into clinical development and to progress additional programs in its preclinical pipeline.
Led by Per Hellsund, President & CEO, Cybrexa is a biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells.
The company’s lead candidate, CBX-11 (alphalex™-rucaparib), is in preclinical development with advancing plans to initiate clinical development by 1Q 2020.
Source. FinSMEs, Staff, June 20, 2019
***
This post was brought to you by Woewoda Communications, your partner in the venture capital, private equity and startup markets; offering strategic communications, public relations & investor relation services to Canadian VCs, PEs, Angels, Endowments/Trusts, Family Offices, and Canadian startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.
Are you a Canadian GP/LP/CI or a Canadian startup that needs to grow or scale? Give us a call! One of our representatives would love to explain how we vertically design, and then systematically layer each of our communication platforms to effectively reach niche target audiences for our clients. WC offers a unique synergistic approach to effectively communicate our client's message to their target audience.
Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa and Halifax.
No comments:
Post a Comment